---

Dacryocystitis - Detailed Notes

Definition

---

Relevant Anatomy

• Puncta - at the posterior edge of the lid margin, medial one-sixth of each lid
• Canaliculi - 2 mm vertical + 8 mm horizontal; superior and inferior unite (>90%) into a common canaliculus
• Rosenmüller valve - mucosal flap at the junction of the common canaliculus and lacrimal sac; prevents reflux
• Lacrimal sac - 10-12 mm long, lies in the lacrimal fossa between the anterior and posterior lacrimal crests
• Nasolacrimal duct (NLD) - 12-18 mm long, opens into the inferior nasal meatus
• Valve of Hasner - mucosal fold at the distal NLD opening

TIP: A mass below the medial canthal tendon = dacryocystitis. A mass above the medial canthal tendon = suspect lacrimal sac tumor.

---

Classification / Types

1. Acute Dacryocystitis

• Subacute onset of pain in the medial canthal area
• Epiphora (excessive tearing)
• A very tender, tense red swelling at the medial canthus
• Commonly progresses to abscess formation
• Associated preseptal cellulitis may occur
• Fever, chills
• Mucoid or purulent discharge expressible from the punctum on pressure over the lacrimal sac

• Lacrimal sac abscess
• Preseptal/orbital cellulitis
• Rarely: fistula formation (sac-skin fistula), facial cellulitis

---

2. Chronic Dacryocystitis

• Chronic epiphora - the dominant symptom
• Chronic or recurrent unilateral conjunctivitis
• A mucocele: painless swelling at the inner canthus (may be absent)
• Pressure over the sac produces mucopurulent canalicular reflux even without obvious swelling
• No acute pain or erythema (unlike acute type)

---

3. Neonatal / Congenital Dacryocystitis

• Pain, tearing, redness, discharge from birth
• Dacryocystocele: bluish-hued mass at the nasolacrimal region
• May be bilateral (if bilateral, assess for nasal obstruction)

---

Pathophysiology

• The primary trigger is obstruction anywhere along the lacrimal drainage system, most commonly at the nasolacrimal duct
• In adults: commonly from primary acquired nasolacrimal duct obstruction (PANDO), often idiopathic, exacerbated by chronic nasal/sinus disease, trauma, neoplasm, or scarring
• In neonates: failure of the valve of Hasner to open (membranous obstruction)
• In children: secondary to viral upper respiratory tract infections causing mucosal edema

• Obstruction causes tears and mucus to pool in the lacrimal sac
• Stagnant secretions create a warm, moist, nutrient-rich environment ideal for bacterial proliferation

• Normal commensal organisms colonize the stagnant mucus
• Common pathogens:
  • Streptococcus pneumoniae (most common in adults)
  • Staphylococcus aureus and other staphylococci
  • Haemophilus influenzae (especially in children)
  • MRSA (in nosocomial/resistant cases)
  • Streptococcal species

• Bacterial infection triggers acute inflammation of the sac wall
• The sac dilates with pus, producing the classic painful swelling
• Surrounding tissues (preseptal) may become involved

• Abscess may point and spontaneously drain through the skin, creating a dacryocystocutaneous fistula
• Infection can spread posteriorly to the orbit (orbital cellulitis) - a sight- and life-threatening complication

---

Microbiology Summary

---

Clinical Evaluation

• Onset, duration, pain, fever, prior episodes (recurrence), nasal disease, trauma, prior ocular surgery

1. Inspection: Location of swelling (below vs. above medial canthal tendon), extent of erythema
2. Pressure test: Apply gentle pressure over the lacrimal sac with a cotton-tipped swab - express discharge from the punctum (positive = confirming dacryocystitis)
3. Evaluate for orbital signs: Pupillary response, extraocular motility, proptosis (rule out concurrent orbital cellulitis)
4. Gram stain and blood agar culture of expressed discharge. In children: use chocolate agar (for H. influenzae)
5. CT scan of orbits and paranasal sinuses: in atypical, severe, or antibiotic-unresponsive cases

---

Differential Diagnosis

---

Management

A. Acute Dacryocystitis

Medical Management

• Cephalexin 500 mg p.o. q6h, OR
• Amoxicillin/clavulanate 500/125 mg t.i.d. or 875/125 mg b.i.d.
• If MRSA suspected: TMP-SMX (double-strength) 160/800 mg p.o. q12h OR Clindamycin 300 mg p.o. t.i.d.

• Amoxicillin/clavulanate 25-45 mg/kg/day p.o. in two divided doses (max 90 mg/kg/day)
• Alternative: Cefpodoxime 10 mg/kg/day in two divided doses (max 400 mg/day)

• Flucloxacillin or co-amoxiclav orally

• Hospitalize + Cefazolin 1 g i.v. q8h
• Transition to oral antibiotics once clinically improving
• Total course: 10-14 days

• Hospitalize + Cefuroxime 50 mg/kg IV q8h (up to 100 mg/kg/day)
• OR Cefazolin 33 mg/kg IV q8h
• Penicillin-allergic: Clindamycin 10 mg/kg IV q6h
• MRSA suspected: Vancomycin 10-13 mg/kg IV q6-8h

• Warm compresses to the inner canthal region for 5-10 minutes q.i.d.
• Gentle massage
• Topical antibiotics (e.g., trimethoprim/polymyxin B q.i.d.) - adjunct only, not sufficient alone
• Analgesics (acetaminophen ± codeine) p.r.n.

Surgical Management

1. Incision and Drainage (I&D)
   • Indicated when abscess is "pointing" (about to drain spontaneously)
   • Risk: persistent sac-skin fistula formation
   • Alleviates pain and hastens healing
2. Dacryocystorhinostomy (DCR)
   • Creates an anastomosis between the lacrimal sac and nasal mucosa, bypassing the NLD obstruction
   • Performed after acute infection has resolved
   • Indications: following acute dacryocystitis (to prevent recurrence), chronic dacryocystitis, fistula closure
   • Can be performed externally (ext-DCR) or endoscopically (endo-DCR)
   • A recent 2025 systematic review confirms external DCR as an evidence-based approach: External DCR - current evidence (PMID 38689455)

---

B. Chronic Dacryocystitis

• Definitive treatment: Dacryocystorhinostomy (DCR)
• DCR creates a new drainage route from the lacrimal sac to the nasal cavity
• Antibiotic therapy alone is insufficient for chronic disease
• Topical fluoroquinolones may be used as temporizing treatment

---

C. Congenital / Neonatal Dacryocystitis

• Crigler massage (lacrimal sac massage): compress/massage 4-6 times daily
• Topical antibiotics (e.g., fluoroquinolone drops q.i.d.)
• Approximately 80% resolve spontaneously by 6-12 months of age

• Indicated if conservative management fails, or dacryocystitis persists
• Optimal timing: 6-10 months of age
• Single probing is curative in ~90% of cases before 14 months
• Perform under general anesthesia in infants

---

Key Clinical Pearls

---

Summary Flowchart

NLD Obstruction
      ↓
Stasis of secretions in lacrimal sac
      ↓
Bacterial colonization (S. pneumoniae, S. aureus, H. influenzae)
      ↓
Acute Dacryocystitis ←──────────────── Chronic Dacryocystitis
(pain, erythema, swelling,              (epiphora, mucocele, recurrent
 fever, abscess)                         conjunctivitis - painless)
      ↓                                        ↓
Oral/IV antibiotics +                       DCR (definitive)
warm compresses
± I&D if pointing abscess
      ↓
Post-acute: DCR to prevent recurrence

---

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed., pp. 110-111, 125
• The Wills Eye Manual, 8th ed., Section 6.9, pp. 399-402
• Tintinalli's Emergency Medicine: A Comprehensive Study, Section 122
• Textbook of Family Medicine, 9th ed., pp. 349-350
• External DCR systematic review, Locatello et al., Eur J Ophthalmol 2025 (PMID 38689455)